Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

Journal of Patient-Reported Outcomes

Table 4 SF-12v2 and SIBDQ scores for the maintenance phase sample at acute and maintenance phase visits

		Baseline		Week 8		Month 12			Post hoc comparisons (Bonferroni-adjusted P [α/3])
	N	LS Mean	SE	LS Mean	SE	LS Mean	SE	P	Baseline vs. Week 8	Baseline vs. Month 12	Week 8 vs. Month 12
SF-12v2
Physical functioning	456	46.3	0.46	52.6	0.36	52.6	0.40	‡	‡	‡	1.0000
Role physical	456	44.5	0.38	51.7	0.29	51.2	0.39	‡	‡	‡	0.8573
Bodily pain	455	43.7	0.44	54.1	0.27	52.6	0.41	‡	‡	‡	†
General health	456	41.2	0.49	51.1	0.38	50.9	0.53	‡	‡	‡	1.0000
Vitality	456	47.3	0.45	55.7	0.42	56.0	0.51	‡	‡	‡	1.0000
Social functioning	456	43.1	0.45	51.8	0.34	50.7	0.44	‡	‡	‡	0.0666
Role emotional	456	41.9	0.47	49.9	0.35	49.8	0.42	‡	‡	‡	1.0000
Mental health	456	44.5	0.45	53.5	0.39	53.7	0.48	‡	‡	‡	1.0000
PCS	456	45.0	0.38	52.6	0.27	52.0	0.37	‡	‡	‡	0.3256
MCS	456	43.6	0.45	52.2	0.36	52.3	0.44	‡	‡	‡	1.0000
SIBDQ
Bowel symptoms	406	12.8	0.17	18.1	0.13	17.3	0.20	‡	‡	‡	‡
Systemic symptoms	405	9.1	0.14	11.5	0.11	11.4	0.13	‡	‡	‡	0.6393
Emotional function	404	13.1	0.21	17.4	0.16	17.0	0.21	‡	‡	‡	0.1070
Social function	406	9.2	0.16	12.6	0.10	12.2	0.14	‡	‡	‡	*
Total score	404	44.2	0.57	59.7	0.43	57.8	0.63	‡	‡	‡	†

LS least squares, MCS mental component summary, PCS physical component summary, SE standard error, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire
Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
Week 8 includes early withdrawal visits during the acute phase. “Month 12” includes early withdrawal visits during the maintenance phase
*P < 0.05, †P < 0.01, ‡P < 0.001